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Smoking is a well-established risk factor for hidradeni-
tis suppurativa (HS). Up to 90% of patients with HS are 
active or former smokers [1]. The pathogenic role of 
smoking in HS is highlighted by the better long-term 
prognosis seen in patients who quit smoking [2]. There-
fore, smoking cessation could be a crucial part of the 
management of HS. We aimed to assess whether nicotine 
dependency, a patient’s confidence in their ability to re-
frain from smoking, and readiness to quit differed be-
tween HS patients and controls. 
A cross-sectional study was performed among consec-
utive, active-smoking patients with HS visiting the spe-
cialised HS outpatient clinic of the Erasmus University 
Medical Center and its affiliated outpatient clinic Derma-
Haven in Rotterdam, The Netherlands, between August 
2018 and April 2019. Randomly selected, currently smok-
ing, non-HS patients attending the Department of Der-
matology were included as controls. All patients filled out 
a questionnaire on their smoking habits and 3 additional, 
validated smoking-related questionnaires: the Fäger-
strom Test for Nicotine Dependence (FTND), which as-
sesses the degree of dependency [3]; the Smoking Self-
Efficacy Questionnaire 12 (SEQ-12), which assesses a pa-
tient’s confidence in their ability to refrain from smoking 
[4], and Readiness to Quit Smoking (RtQ) in the past 12 
months and within the next 6 months. Patient character-
istics were collected through the HiScreen Registry 
(MEC-2016-426) and/or patient charts. Differences be-
tween HS patients and controls were assessed using Stu-
dent t tests, Mann-Whitney U tests, or χ2 tests where ap-
propriate. The study was approved by the local Institu-
tional Review Board (MEC-2018-1127). All patients gave 
their consent for study participation. 
In total 108 HS patients and 111 controls were includ-
ed (Table 1). Most of the control patients attended the 
clinic for eczema (23%; the vast majority atopic dermati-
tis), psoriasis (16%), or a cutaneous malignancy (12%). 
The included controls were significantly older compared 
with the HS patients (mean age 45 ±14 vs. 41 ±13 years, 
respectively, p = 0.01). Patients with HS did not show a 
significantly different degree of smoking dependency, 
measured with the FTND, compared with controls. 
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There was no significant difference between the propor-
tion of HS patients and controls who had attempted to 
quit smoking in the past 12 months (47.2 vs. 37.8%, p = 
0.17), or who were considering quitting smoking in the 
upcoming 6 months (59.6 vs. 51.4%, p = 0.23). Nicotine 
dependency including the effect of intrinsic or extrinsic 
stimuli, or readiness to quit smoking among HS patients 
were not significantly associated with either age, body 
mass index, disease duration, or disease severity (Hurley 
stage).
In summary, this study shows that smoking HS pa-
tients experience the same level of nicotine dependency, 
and comparable readiness to quit as controls. The major 
strengths of this study are the use of validated question-
naires and a control group. The main limitation is that the 
groups are relatively small and not matched, for example, 
for age. However, we do not expect the difference in age 
between the groups to have influenced the results as a 
previous study among 1,378 Dutch smokers demonstrat-
ed that there was no correlation between age and FTND 
score [5].
Smoking cessation improves the long-term prognosis 
of HS as well as general health. Therefore, motivating pa-
tients for and supporting them through the process of 
smoking cessation is an integral part of the treatment of 
HS. Guidance in smoking cessation is tapered to a pa-
tient’s individual level of dependency, their readiness to 
quit, and their confidence in their ability to refrain from 
smoking. This study suggests that smoking cessation 
among HS patients can be attempted through regular in-
Table 1. Characteristics and smoking habits of patients with HS and controls
HS (n = 108) Controls
(n = 111)
p value
Female sex 72 (66.7) 61 (55.0) 0.10
Age, years 41±13 45±14 0.01
BMI 27.65±5.64




Age at onset of HS, years 20 (14–30)
Missing 8
Hurley stage
Hurley stage I 65 (60.2)
Hurley stage II 40 (37.0)
Hurley stage III 3 (2.8)
Age when started smoking, years 16 (14–17) 16 (14–18) 0.32
Missing 0 2
Total cigarettes a day 14 (8–20) 10 (7–15) 0.06
FTND score 3.0 (2.0–5.0) 3.0 (1.0–5.0) 0.07
Missing 1 1
SEQ-12 score 30.0 (24.0–40.0) 29.5 (22.0–40.0) 0.34
Missing 11 17
Intrinsic stimuli 16.7±6.8 15.4±6.2 0.17
Missing 3 5
Extrinsic stimuli 15 (11–22) 14 (9–21) 0.07
Missing 7 16
RtQ past 12 months
Yes 51 (47.2) 42 (37.8) 0.17
RtQ next 6 months
Yes 62 (59.6) 55 (51.4) 0.23
Missing 4 4
Data are presented as n, n (%), the mean ± SD, or median (IQR). BMI was only collected for patients with HS. 
HS, hidradenitis suppurativa; FTND, Fägerstrom Test for Nicotine Dependence; SEQ-12, Self-Efficacy Question-
naire 12; RtQ, Readiness to Quit Smoking.
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terventions without the need for different strategies, as 
nicotine dependency and factors influencing self-efficacy 
and readiness to quit do not differ between HS patients 
and controls. 
Key Message
Nicotine dependency and readiness to quit smoking are similar 
between hidradenitis suppurativa patients and controls.
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